Media Room

Media Downloads

Fact Sheet

TANGO Explainer

Fact Sheet

Dravet Syndrome

Fact Sheet

Autosomal Dominant Optic Atrophy (ADOA)

Photo

Edward M. Kaye, M.D., CEO & Director

Illustration

TANGO-ASO

Logo

Stoke Therapeutics

Stoke In the News

Experts from Stoke are consulted for input to inform news coverage about our innovative science, the serious diseases we are working to address, and the industry we are proud to be a part of.

Learn More

Latest Press Releases

Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer

April 17, 2024

Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

April 4, 2024

Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering

March 28, 2024

Learn more about our science

View all our publications and presentations

Featured Publications

Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model of Dravet syndrome

Science Translational Medicine

August 26, 2020

Read Full Article

Antisense oligonucleotide modulation of non-productive alternative splicing upregulates gene expression

Nature Communications

July 9, 2020

Read Full Article

Cookie	Duration	Description
cookielawinfo-checkbox-advertisement	1 year	Set by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Cookie	Duration	Description
_ga	2 years	The _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_gat_gtag_UA_111444387_1	1 minute	Set by Google to distinguish users.
_gid	1 day	Installed by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.

Media Downloads

Fact Sheet

Fact Sheet

Fact Sheet

Photo

Illustration

Logo

Stoke In the News

Latest Press Releases

Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer

Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering

Learn more about our science

Featured Publications

Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model of Dravet syndrome

Antisense oligonucleotide modulation of non-productive alternative splicing upregulates gene expression

More About Stoke on Twitter